Two distinct monoclonal antibodies, one to pertussis toxin subunit S2, called 9G8, and another to subunits S2 and S3, called 11E6, were generated from the hybridomas of myeloma SP2/0 and spleen cells of BALB/c mice immunized mainly with the subunit S234 complex. Binding ability of 9G8 and 11E6 to the subunits was confirmed by the enzyme-linked immunosorbent assay and immunoblotting analysis. Generation of 11E6 bound to both S2 and S3 might mean that there is common antigenicity between S2 and S3. Neutralizing activities of 9G8 and 11E6 on various biological activities of pertussis toxin, including ADP-ribosyltransferase and leukocytosis-promoting, islet-activating, permeability-increasing, Chinese hamster ovary (CHO) cellclustering, and hemagglutinating activities, were compared with those of anti-Sl monoclonal antibodies 1B7 and 3F10, which were isolated and characterized in a previous study (H. Sato, A. Ito, J. Chiba, and Y. Sato, Infect. Immun. 46:422-428, 1984). 1B7 and 3F10 neutralized ADP-ribosyltransferase activity of pertussis toxin or Si, but 9G8 and 11E6 did not. 1B7 showed very potent neutralization against leukocytosis-promoting, islet-activating, permeability-increasing, and CHO cell-clustering activities of pertussis toxin, but 3F10 did not, although anti-ADP-ribosyltransferase activities of both antibodies were identical. 11E6 neutralized leukocytosis-protnoting, islet-activating, CHO cell-clustering, and hemagglutinating activities but not permeability-increasing activity. 9G8 showed slight neutralization of leukocytosis-promoting and CHO cell-clustering activities. Specific activities of 1B7 and ilE6 in each neutralization test were higher than or almost comparable to those of polyclonal antibodies to pertussis toxin. The neutralizing mechanism of 1B7 and ilE6 in leukocytosis-promoting activity was compared. liE6 seemed to interfere with the binding of pertussis toxin to receptors on mouse spleen cells.
Pertussis toxin (PT) is one of the various toxic proteins produced by virulent Bordetella pertussis, the microorganism that causes whooping cough. The toxin elicits a wide variety of biological activities, such as leukocytosis promotion (LP), histamine sensitization, insulin secretion, and immunopotentiating effects in experimental animals. In addition, PT detoxified with Formalin, pertussis toxoid (PTd), protects mice challenged intracerebrally or by aerosol with virulent B. pertussis (17, 18) . PTd is, therefore, an important constituent in the acellular vaccine against whooping cough in Japan (20) . However, PT may also be the cause of the harmful side effects associated with the vaccine. Therefore, the toxin must be detoxified for vaccine. Such detoxification should abolish the pathobiological activities of PT without hampering its immunogenicity. What epitopes on PT must be or need not be abolished? Studies on the structure-function relationship of the toxin are, therefore, important not only in resolving the pathogenesis of whooping cough or the regulatory mechanism in PT toxification but also in the development of a safer and more effective vaccine.
The toxin structure is a hexamer composed of five subunits, designated S1 through S5, and is considered as one of the A-B toxins (24) ; S1, the biggest subunit, is the A protomer which has ADP-ribosyltransferase activity (5) . The residual subunits form a B oligomer which is responsible for binding of the toxin molecule on the mammalian cell surface, allowing the A protomer to enter the cell (25) . The B oligomer consists of two dimers, S24 and S34, and the smallest C subunit, S5 . The location of active sites of the different biological activities on each subunit has been * Corresponding author. investigated with recombinants of isolated subunits. Among the biological activities of PT, hemagglutination (HA) and mitogenicity were caused by S24 or S34 (13, 16) and B oligomer (25) , respectively. All other important activities such as leukocytosis-promoting, histamine-sensitizing, or islet-activating (IA) activities, however, were not recognized by a defective combination of subunit proteins, although every activity was elicited by the reconstituted PT with all five subunits (21, 24) . Nogimori et al. (11) (12) (13) attempted chemical modifications of PT to resolve the role of each subunit in the various activities and proposed a dual mechanism for the binding of PT to mammalian cells, i.e., monovalent binding via S24 or S34 and divalent binding via both S24 and S34 complexes.
We have been using monoclonal antibodies (MAbs) to clarify the essential structure of PT as protective antigen and its role in adverse reactions to the vaccine from a prophylactic standpoint (16, 18 The methods of dissociation of PT and isolation of the subunits were described in a previous report (21 To obtain a high titer of the antibodies, the hybridomas were injected into BALB/c mice primed with pristane (2,6,10,14-tetra-methylpentadecane, Aldrich Chemical Company, Inc., Milwaukee, Wis.). The antibodies in the ascites were precipitated with ammonium sulfate at 50% saturation and then purified by chromatography with hydroxylapatite (23) . The purity of all IgG preparations was evaluated by disc gel electrophoresis at pH 9.4. The protein concentration of the purified IgG was estimated from the A280 value with E1% = 15. All experiments were performed with the purified IgG preparation of MAbs.
Binding activity of the antibodies to PT and its subunits. Binding activity of the antibodies to antigens was measured by the ELISA system essentially by the method reported previously (16) , and ELISA units per milliliter were estimated from the dose-response curves by the parallel-line assay method with reference antibody M5. The binding activity of the antibodies was given by PT (14) .
To determine ADP ribosyltransferase (ADPR) activity, the membrane was prepared from the C6 cells by the method of Katada et al. (4) . ADP-ribosylation was carried out by mixing in an Eppendorf centrifuge tube the following in sequence. First, 4 ,1 of PT (500 ,ug/ml) and 4 ,ul of 100 mM dithiothreitol were mixed in 100 ,1 of 100 mM Tris hydrochloride-50 mM NaCl (pH 7.5), and incubated at 35°C for 10 min. Then 50 R1 of reaction mixture, which consisted of 25 mM Tris hydrochloride (pH 7.5), 40 mM thymidine, 4 mM ATP, 0.4 mM GTP, and 4 mM EDTA, and 20 RI of the membrane preparation (500 ,ug/ml) was added to the reduced PT solution. The reaction was started by the last addition of PT (500 ,ug/ml) and 100 ,ul of antibody diluted in 100 mM Tris hydrochloride-50 mM NaCI (pH 7.5) were incubated at room temperature for 30 min before addition of dithiothreitol.
After incubations at 35°C for 30 min, the reactions were stopped by the addition of 1 ml of ice cold buffer consisting of 25 mM Tris hydrochloride-2.5 mM MgCl2 (pH 7.5) centrifuged at 11,500 x g for 5 min and washed twice with 1 ml of the buffer by centrifugation. The washed membranes were dissolved in 50 ,ul of 2% SDS. The dissolved membranes were mixed with a scintillation cocktail, and the radioactivity of 32p was measured in a scintillation counter.
The neutralizing dose of MAb was expressed in micrograms of the antibody by which the incorporation of [32P]ADPribose into the membrane protein with 2 ,ug of PT was inhibited to 50%. To confirm the 32p incorporation into a 41-kilodalton protein of the membrane (5), the washed membrane and molecular weight marker were dissolved in Laemmli sample buffer (6) and subjected to SDS-PAGE in 12.5% polyacrylamide gels. After being stained, the gel was dried and subjected to autoradiography.
LP and IA activities. Both activities were assayed as described previously (16) . LP activity was measured by i.v. injection of the test samples and PTRef.7 into five female SPF SLC-DDY mice (Shizuoka Laboratory Animal Center, Hamamatsu, Japan) and was calculated in LP units from the relative value for PTRef.7 (10,000 LP units per ml). Leukocytes (WBC) in tail vein blood 3 days after injection were counted. The net WBC count was obtained by subtraction of the count of normal mice.
For IA activity, the mice were starved overnight after the WBC count for the LP assay. Blood samples (20 ,ul) taken from the tail vein of the five mice 15 min after intraperitoneal injection of 50% glucose (0.5 ml per mouse) were pooled in 400 ixl of phosphate-buffered saline (PBS) for a fivefold dilution and were centrifuged to remove the blood cells. The insulin in the sera was measured by radioimmunoassay and ELISA.
For the assay of neutralizing antibody activity against LP and IA activities of PT, serially diluted antibody preparations were mixed with an equal volume of PTRef.7 diluted with PBS containing 0.2% gelatin to a concentration of 1.0 ,ug/ml. When a mixture of two MAbs was examined, each MAb was mixed with equivalent amounts of protein. After reacting for at least 30 min at room temperature, 0.2 ml of the mixture was injected into the tail veins of mice. Five mice per dose were used. After injection (3 and 4 days) of the mixture, WBC and blood insulin (respectively) were measured as stated above, and the percentages of LP and IA activities neutralized were estimated. Neutralizing doses for 0.1 ,ug of PT were calculated from the regression lines (y = a + b log x) of the percent neutralization (y), which was the mean of at least four experiments on antibody doses (x) per mouse at 50% neutralization. a is the percent neutralization with 1 ,ug of the antibody, and b is a regression coefficient.
Calculation of relative neutralizing activity to the reference antibody, M5, by the parallel-line assay method was impossible not only in this assay but also in the following other assays, because of the differences in regression coefficients (b) between each MAb and M5.
PI activity. The assay of anti-permeability-increasing (PI) activity of antibodies was performed essentially according to Sakuma et al. (15) . Briefly, serial dilutions of the test antibodies were mixed with an equal amount of PT (2 pg/ml) and incubated for 1 h at 37°C, and then 0.1 ml of the mixtures was injected intradermally (in duplicate) into the depilated back skin of adult New Zealand White rabbits. After 7 h, the rabbits were injected i.v. with 1. tivities by each or a combination of four MAbs to six different biological activities of PT were examined, and neutralizing doses were estimated as described in Materials and Methods (Table 2 ; 1H2 was omitted from this table because 1H2 did not show any significant neutralization activity to PT in both previous [16] and present studies).
In the neutralization test for ADPR activity, 32p incorporation into the C6 cell membrane protein by 2 ,ug of PT was inhibited with 0.6 ,ug of 1B7 or 3F10, but 9G8 and 11E6 showed no and a very little inhibition, respectively. ADPR activity with purified Si was also neutralized by 1B7 and 3F10 (data not shown). 32p was incorporated into the 41-kilodalton membrane protein of C6 cells by PT or S1 treatment (Fig. 2) . It was confirmed that both 1B7 and 3F10 inhibited the incorporation by PT but 11E6 and 9G8 did not. Neutralization of LP and IA activities was almost parallel in all antibodies. 1B7 neutralized both LP and IA activities of PT (0.1 jig per mouse) with 0.2 and 0.5 ,ug, respectively, but 3F10 did not for either activity. 11E6 showed clear neutralization, but 9G8 showed rather low neutralization. When two MAbs were mixed, every combination of antibody showed significant neutralization and steeper slopes in the dose-response curves of the neutralization than did any single MAb. In particular, 1B7 mixed with 9G8 or 11E6 showed the same slope as that for M5. In the neutralization test for LP activity, the regression coefficients (b) of 1B7, 9G8, 11E6, and M5 were 31, 29, 40, and 74, respectively.
For PI activity of PT, only 1B7 neutralized, although the slope of the dose-response curve was less steep. Any other MAb could hot neutralize PI, whereas every combination of two MAbs did. For CC activity of PT, 11E6 showed high neutralizing activity and a regression line as steeply sloped as that for M5. 1B7 and 9G8 also showed significant neutralization, but the slopes were less steep. By the combination of two MAbs, the neutralizing activity increased.
HA inhibition by 11E6 was clear and complete, but that by 1B7 or 3F10 was unclear. The neutralizing activity of a MAb did not increase with any combination of MAbs. A clear negative figure was observed only for 11E6.
Kinetics of neutralization of LP activity by MAb. The time course of neutralization of LP activity by 1B7 and 11E6 was compared (Fig. 3) . At the same time or 1 day after PT administration, both MAbs suppressed the increase of WBC in the blood as well as M5 did.
Next, the effect of MAbs on the binding of PT to spleen cells in vitro was studied by examination of leukocytosis and hyperinsulinemia in mice infused with spleen cells treated with PT and the antibodies (Table 3) ml of PT (3 p.g/ml) and 0.1 ml of 1B7 (400 ,ug/ml), 11E6 (500 p.g/ml), M5 (1,250 ,ug/ml), or PBS (as control) were preincubated for 30 min at room temperature and then incubated with 0.2 ml of Dulbecco modified Eagle medium (DMEM) (without cells) or spleen cell suspension (108 per ml) at 37°C for 1 h in a CO2 incubator. In experiment B, 0.2 ml of PT (3 p,g/ml) and 0.2 ml of the spleen cell suspension (108 per ml) were preincubated at 37°C for 1 h in a CO2 incubator and then incubated with the antibodies used in experiment A for 30 min at room temperature. After the incubation, each reaction mixture in both experiments was diluted with chilled DMEM (1.5 ml) and divided in half. One part, the uncentrifuged reaction mixture which contains free antibody, was infused into four normal syngeneic mice by i.v. injection (0.2 ml per mouse). The other part of the reaction mixture was centrifuged twice 400 x g for 10 min to obtain a spleen cell suspension without free PT and antibody. The cells were resuspended in DMEM to 1.0 ml, and then 0.2 ml was infused i.v. into normal syngeneic mice. In both experiments, LP and IA activities were estimated as described in Materials and Methods. All three antibodies neutralized the LP activity equally well in the mice infused with the uncentrifuged reaction mixture of experiments A and B ( (7, 8, 10) . Since these investigators reported amino acid homology of 67 to 70% between S2 and S3 (8, 10) , 11E6 and 9G8 might recognize homologous and nonhomologous regions, respectively. The findings that the binding of 1B7 and 3F10 to PT was not inhibited in the Hp-PT and SRBCM-PT ELISA systems but that the binding of 9G8, 11E6, and 1H2 was may support the report that S2, S3, and S4 may be involved in the membrane penetration step of the intoxication process (9) .
The differences in toxin-neutralizing activities of distinct MAbs must reflect the differences in mode of action in each activity of PT. 1B7 neutralized every PT activity tested and ADPR, LP, IA, PI, CC, and HA activities, although the inhibition to HA was incomplete. The Fab fragment of 1B7 also neutralized CC activity (data not shown). These results suggest that an epitope recognized or blocked by 1B7 plays an important role in all the biological activities except HA. 11E6 neutralized LP, IA, CC, and HA activities but, contrary to our expectation, did not neutralize PI activity. If 11E6 bound directly to the essential sites of PT for binding to a putative receptor on a target, neutralization of PI might also be expected. The reason why 11E6 could not neutralize did not significantly neutralize any of the PT activities in the same way as 1B7 did, although anti-ADPR activities of both 1B7 and 3F10 were identical. ADPR activity of PT was assayed in a cell-free system with the use of C6 cell membrane protein, but if this activity had been assayed in a whole-cell system, different anti-ADPR activity might have been observed between 1B7 and 3F10. Neutralizing activity of 9G8 was low but significant for LP and CC activities. In this study, only six of the numerous activities of PT have been examined by a neutralization test with a whole IgG preparation of the MAb. To understand the role of each PT epitope, however, more PT activities should be tested, not only with whole IgG but also with Fab fragments of the MAbs.
When the dose-response regression lines of 1B7 and 11E6 were compared, the slope of former was always less steep than that of the latter. One of the reasons for the steep slope might be that 11E6 could bind two different sites, S2 and S3, on PT molecules. Mixtures of two MAbs neutralized every biological activity at doses smaller than or almost comparable to the neutralizing doses of M5 and showed doseresponse curves with steeper slopes than individual MAbs did. In particular, the mixture of 1B7 and 11E6 always showed strong neutralization for every PT activity and the same slope as M5 did. The presence of 1B7 and 11E6 gives a decisive advantage for neutralization of every PT activity. Also, mixtures of 1B7 and 11E6 can be used as well as M5 as the reference antibody for assays of various activities of the antibodies.
It has been reported that anti-PT conventional antibody or 1B7 suppresses leukocytosis even 2 to 4 days after PT injection (3; H. Sato and Y. Sato, Semin. Infect. Dis., in press). In the present study, 11E6, as well as 1B7 or M5, also suppressed leukocytosis. It was thus determined whether 11E6 can neutralize LP activity even after the binding of PT to the target cells. The mode of neutralization by 1B7 and 11E6 of LP and IA activities was investigated in an infusion experiment with spleen cells chosen as the targets in vivo. 11E6 seemed to interfere with the binding of PT to the spleen cells. It still showed some neutralization against PT which prebound to the cells. Neutralization with 1B7 was weakened by centrifugation, and resuspension of the cells reacted with PT and 1B7. 1B7 may detach more easily from the cell-PT-MAb complex by being washed compared with the effects for 11E6. The results of cell infusion experiments suggest that PT interacts reversibly or successively with target cells in vivo as reported previously (1, 3, 22) and also suggest that the epitope for 1B7 may not be related to the initial binding site of the cell. As four distinct MAbs were characterized in this study, they can be used to analyze the complex process of PT activity in vivo by an in vitro system.
In addition, the MAbs are powerful tools for understanding the pathogenic mechanism of PT and for investigating important structures of PT for vaccine production and human MAb production.
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